Clinical Trial Detail

NCT ID NCT01931163
Title NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer
Recruitment Completed
Gender female
Phase Phase II
Variant Requirements yes
Sponsors The Methodist Hospital System
Indications

triple-receptor negative breast cancer

Therapies

Everolimus

Age Groups: adult

Additional content available in CKB BOOST